ERAS
Price
$2.92
Change
+$0.14 (+5.04%)
Updated
Nov 21, 04:59 PM (EDT)
Capitalization
828.44M
117 days until earnings call
Intraday BUY SELL Signals
RVMD
Price
$70.86
Change
+$0.98 (+1.40%)
Updated
Nov 21, 04:59 PM (EDT)
Capitalization
13.7B
100 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ERAS vs RVMD

Header iconERAS vs RVMD Comparison
Open Charts ERAS vs RVMDBanner chart's image
Erasca
Price$2.92
Change+$0.14 (+5.04%)
Volume$27.87K
Capitalization828.44M
Revolution Medicines
Price$70.86
Change+$0.98 (+1.40%)
Volume$27.84K
Capitalization13.7B
ERAS vs RVMD Comparison Chart in %
ERAS
Daily Signal:
Gain/Loss:
RVMD
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ERAS vs. RVMD commentary
Nov 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and RVMD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 22, 2025
Stock price -- (ERAS: $2.92 vs. RVMD: $70.86)
Brand notoriety: ERAS and RVMD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 91% vs. RVMD: 85%
Market capitalization -- ERAS: $828.44M vs. RVMD: $13.7B
ERAS [@Biotechnology] is valued at $828.44M. RVMD’s [@Biotechnology] market capitalization is $13.7B. The market cap for tickers in the [@Biotechnology] industry ranges from $108.28B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileRVMD’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • RVMD’s FA Score: 0 green, 5 red.
According to our system of comparison, both ERAS and RVMD are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 3 TA indicator(s) are bullish while RVMD’s TA Score has 2 bullish TA indicator(s).

  • ERAS’s TA Score: 3 bullish, 5 bearish.
  • RVMD’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, both ERAS and RVMD are a bad buy in the short-term.

Price Growth

ERAS (@Biotechnology) experienced а +13.18% price change this week, while RVMD (@Biotechnology) price change was +4.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.01%. For the same industry, the average monthly price growth was -3.31%, and the average quarterly price growth was +62.87%.

Reported Earning Dates

ERAS is expected to report earnings on Mar 19, 2026.

RVMD is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (-1.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RVMD($13.7B) has a higher market cap than ERAS($828M). RVMD YTD gains are higher at: 62.003 vs. ERAS (16.335). ERAS has higher annual earnings (EBITDA): -135.93M vs. RVMD (-883.71M). RVMD has more cash in the bank: 2.14B vs. ERAS (301M). ERAS has less debt than RVMD: ERAS (49.4M) vs RVMD (133M). ERAS (0) and RVMD (0) have equivalent revenues.
ERASRVMDERAS / RVMD
Capitalization828M13.7B6%
EBITDA-135.93M-883.71M15%
Gain YTD16.33562.00326%
P/E RatioN/AN/A-
Revenue00-
Total Cash301M2.14B14%
Total Debt49.4M133M37%
TECHNICAL ANALYSIS
Technical Analysis
ERASRVMD
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 4 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
69%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 2 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signal:
Gain/Loss:
RVMD
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BGAIX45.200.13
+0.28%
Baron Global Opportunity Institutional
CSPIX14.16N/A
N/A
Calvert Global Small-Cap Equity I
SKSZX29.27N/A
N/A
AMG GW&K Small Cap Value Z
VKSAX18.38N/A
N/A
Virtus KAR Small-Mid Cap Core A
MKVHX16.84N/A
N/A
MFS International Large Cap Value R6